2013


To access this material please log in or register

Register Authorize
2013/№5

Use of ranolazine in ischemic heart disease

Tatarsky B.A.
Federal State Budgetary Institution, “North-West Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St.-Petersburg 197341

Keywords: hyperpiesis, CAD, treatment, ранолазин

DOI: 10.18087/rhj.2013.5.1858

Ranolazine is a relatively new, unique, extended-release antianginal drug approved for the treatment of stable angina. According to current notions, mechanisms of ranolazine action include selective inhibition of late sodium current and improvement of abnormal ventricular repolarization and contractility. Several randomized studies have demonstrated ranolazine efficacy in increasing the exercise tolerance and reducing both the frequency of anginal attacks and the need for nitroglycerine. Adverse effects included dizziness, constipation, nausea and prolongation of the QTc interval. Ranolazine is a safe supplement to the standard therapy for stable angina.
  1. 2007 Chronic Angina Focused Update of the ACC / AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina. A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina. J Am Coll Cardiol. 2007;50 (23):2264–2274.
  2. Rosamond W, Flegal K, Furie K et al. Heart Disease and Stroke Statistics 2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117 (4):e25–146.
  3. Rosamond W, Flegal K, Furie K et al. Heart Disease and Stroke Statistics 2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117 (4):e25–146.
  4. Лупанов В. П. Ранолазин при ишемической болезни сердца. Рациональная фармакотерапия в кардиологии. 2012;8 (1):103–109.
  5. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика. 2008;6 (приложение 4):40 с.
  6. Boden WE, O'Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356 (15):1503–1516.
  7. Physicians' Desk Reference. 61st ed. Montvale, NJ: Thomson PDR; 2007. –1035–1037pp.
  8. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmaco­kinet. 2006;45 (5):469–491.
  9. Ranexa package insert. CV Therapeutics 2006. Available at http://www.pharmacistelink.com / productinfo / highlights / 2006 / 07 / 11CV_Ranexa_Copy.pdf
  10. Abdallah H, Jerling M. Effect of hepatic impairment on the multiple dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol. 2005;45 (7):802–809.
  11. Jerling M, Abdallah H. Effect of renal impairment on multiple dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther. 2005;78 (3):288–297.
  12. Jerling M, Huan B, Leung K, Chu N et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoco­nazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45 (4):422–433.
  13. Chaitman BR. Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials. J Cardiovasc Pharmacol Ther. 2004;9 (Suppl 1):S47–64.
  14. Anderson JR, Nawarskas JJ. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev. 2005;13 (4):202–210.
  15. MacInnes A, Fairman DA, Binding P et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3‑ketoacyl coenzyme A thiolase. Circ Res. 2003;93 (3):e26–32.
  16. Bers DM, Barry WH, Despa S. Intracellular Na+ regulation in cardiac monocytes. Cardiovasc Res. 2003;57 (4):897–912.
  17. Bers DM. Electrophysiologic basis for the antiarrhythmic treatment. Kluwer Academic Publishers, Dordrecht, The Netherlands, 2001.
  18. Nattel S, Ehrlich JR. Atrial fibrillation. In: Zipes DP, Jalife J. eds. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. –Saunders: Philadelphia; 2004. – p512–521.
  19. Bers DM, Despa S. Cardiac myocytes Ca2+ and Na+ regulation in normal and failing hearts. J Pharmacol Sci. 2006;100 (5):315–322.
  20. Noble D, Noble P. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart. 2006;92 (Suppl 4):iv1‑iv5.
  21. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of (sustained / persistent) sodium current: A potential drug target to reduce intracellular sodium dependent calcium overload and its detrimental effects on cardiomyocyte function, Eur Heart J. 2004; 6 (Suppl 1), I3‑I7.
  22. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92 (Suppl 4):iv6‑iv14.
  23. Yue L, Feng J, Gaspo R et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81 (4):512–525.
  24. Yeh YH, Wakili R, Qi XY et al. Calcium handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs. Circ Arrhythm Electrophysiol. 2008;1 (2):93–102.
  25. Murphy E, Cross H, Steenbergen C. Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res. 1999;84 (12):1469–1470.
  26. Hale S, Leeka J, Kloner R. Improved left ventricular function and reduced necrosis after myocardial ischemia / perfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exp Ther. 2006;318 (1):418–423.
  27. Pepine C, Wolff A. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol. 1999;84 (1):46–50.
  28. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95 (3):311–316.
  29. Chaitman B, Pepine C, Parker J et al Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291 (3):309–316.
  30. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008;372 (9646):1335–1341.
  31. Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43 (8):1375–1382.
  32. Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291 (3):309–316.
  33. Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48 (3):566–575.
  34. Wilson SR, Scirica BM, Braunwald E еt al. Efficacy of ranolazine in patients with chronic angina observations from the rando­mized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53 (17):1510–1516.
  35. Morrow D, Scirica B, Chaitman B et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009;119 (15):2032–2039.
  36. Rich M, Crager M, McKay C. Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris. Am J Geriatr Cardiol. 2007;16 (4):216–221.
  37. Venkataraman R, Belardinelli L, Blackburn B et al. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009;2 (11):1301–1309.
  38. Wu L, Belardinelli L, Fraser H. A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart. J Cardiovasc Pharmacol. 2008;51 (4):372–379.
  39. Kosiborod M, Arnold SV, Spertus JA et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: Results from the TERISA randomized clinical trial. J Am Coll Cardiol. 2013;61 (20):2038–2045.
  40. Koren MJ, Crager MR, Sweeney M. Long term safety of a novel antianginal agent in patients with severe stable angina: the Ranolazine Open Lable Experience (ROLE). J Am Coll Cardiol. 2007;49 (10):1027–1034.
  41. Bersin RM, Wolfe C, Kwasman M et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol. 1994;23 (7):1617–1624.
  42. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF / AHA / ACP / AATS / PCNA / SCAI / STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60 (24):e44‑e164.
Tatarsky B.A. Use of ranolazine in ischemic heart disease. Russian Heart Journal. 2013;12(5):273-281

To access this material please log in or register

Register Authorize
Ru En